Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/21/2025 12:42 PDT] Clearside Biomedical, Inc. (NASDAQ:CLSD), Down By 100% ($0.4) From $0.4 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/21/2025 07:12 PDT] CLSD Expected to Trade Down After Bearish Patterns Develop
• [07/11/2025 07:25 PDT] CLSD Expected to Trade Up After Bullish Patterns Develop
• [06/16/2025 07:11 PDT] CLSD Expected to Trade Up After Bullish Patterns Develop
• [06/06/2025 07:16 PDT] CLSD Expected to Trade Up After Bullish Patterns Develop